Clinical utility of DaTscan™ imaging in the evaluation of patients with parkinsonism: a US perspective

Stuart H. Isaacson, Stanley Fisher, Fiona Gupta, Neal Hermanowicz, Daniel E. Kremens, Mark F. Lew, Kenneth Marek, Rajesh Pahwa, David S. Russell, John Seibyl

Research output: Contribution to journalArticlepeer-review

22 Scopus citations


Introduction: Single photon emission computed tomography (SPECT) with Ioflupane I123 injection (DaTscan™) was approved by the Food and Drug Administration in 2011 for striatal dopamine transporter visualization to assist in the evaluation of adult patients with suspected parkinsonian syndromes. While brain SPECT imaging using DaTscan is a covered service under Medicare policy, there is a lack of consensus on its role in routine clinical practice in the US. Areas covered: To address this issue, an expert group of US-based movement disorders neurologists convened to discuss the clinical utility of DaTscan in movement disorders practices within the US. The group identified and discussed routine clinical scenarios where imaging with DaTscan can provide useful information that may impact management and/or clarify clinical diagnoses. This paper summarizes a consensus reached by the expert group at this meeting. Expert commentary: The major utility of DaTscan imaging is the assistance it provides in distinguishing between nigrostriatal dopaminergic degeneration and non-nigrostriatal degeneration in patients displaying equivocal signs and symptoms of parkinsonism.

Original languageEnglish
Pages (from-to)219-225
Number of pages7
JournalExpert Review of Neurotherapeutics
Issue number3
StatePublished - 4 Mar 2017
Externally publishedYes


  • DaTscan
  • Dopamine transporter
  • diagnosis
  • imaging
  • parkinson’s disease
  • treatment


Dive into the research topics of 'Clinical utility of DaTscan™ imaging in the evaluation of patients with parkinsonism: a US perspective'. Together they form a unique fingerprint.

Cite this